← All trials
NCT03205917
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2017
- Primary completion
- Jul 31, 2019
- Completion date
- Jul 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- Harvard UniversityCollaborator
- Harvard UniversityStudy chair
- Harvard UniversityOverall official - principal investigator
- Ragon Institute of MGH, MIT and HarvardCollaborator
- Harvard UniversityOfficial
- Harvard UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.